Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice

Dipankar Pramanik, Nathaniel R. Campbell, Collins Karikari, Raghu Chivukula, Oliver A. Kent, Joshua T. Mendell, Anirban Maitra

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Mis-expression of microRNAs (miRNA) is widespread in human cancers, including in pancreatic cancer. Aberrations of miRNA include overexpression of oncogenic miRs (Onco-miRs) or downregulation of so-called tumor suppressor TSG-miRs. Restitution of TSG-miRs in cancer cells through systemic delivery is a promising avenue for pancreatic cancer therapy. We have synthesized a lipid-based nanoparticle for systemic delivery of miRNA expression vectors to cancer cells (nanovector). The plasmid DNA-complexed nanovector is approximately 100 nm in diameter and shows no apparent histopathologic or biochemical evidence of toxicity upon intravenous injection. Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1). Systemic intravenous delivery with either miR-34a or miR-143/145 nanovectors inhibited the growth of MiaPaCa-2 subcutaneous xenografts (P < 0.01 for miR-34a; P < 0.05 for miR-143/145); the effects were even more pronounced in the orthotopic (intrapancreatic) setting (P < 0.0005 for either nanovector) when compared with vehicle or mock nanovector delivering an empty plasmid. Tumor growth inhibition was accompanied by increased apoptosis and decreased proliferation. The miRNA restitution was confirmed in treated xenografts by significant upregulation of the corresponding miRNA and significant decreases in specific miRNA targets (SIRT1, CD44 and aldehyde dehydrogenase for miR34a, and KRAS2 and RREB1 for miR-143/145). The nanovector is a platform with potential broad applicability in systemic miRNA delivery to cancer cells.

Original languageEnglish (US)
Pages (from-to)1470-1480
Number of pages11
JournalMolecular Cancer Therapeutics
Volume10
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

MicroRNAs
Pancreatic Neoplasms
Growth
Neoplasms
Heterografts
Carrier Proteins
Plasmids
Down-Regulation
Aldehyde Dehydrogenase
Neoplastic Stem Cells
Gene Regulatory Networks
Intravenous Injections
Nanoparticles
Cell Survival
Up-Regulation
Apoptosis
Lipids
DNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. / Pramanik, Dipankar; Campbell, Nathaniel R.; Karikari, Collins; Chivukula, Raghu; Kent, Oliver A.; Mendell, Joshua T.; Maitra, Anirban.

In: Molecular Cancer Therapeutics, Vol. 10, No. 8, 08.2011, p. 1470-1480.

Research output: Contribution to journalArticle

Pramanik, Dipankar ; Campbell, Nathaniel R. ; Karikari, Collins ; Chivukula, Raghu ; Kent, Oliver A. ; Mendell, Joshua T. ; Maitra, Anirban. / Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. In: Molecular Cancer Therapeutics. 2011 ; Vol. 10, No. 8. pp. 1470-1480.
@article{f0ea100740b94a8195d73ed90ade1b21,
title = "Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice",
abstract = "Mis-expression of microRNAs (miRNA) is widespread in human cancers, including in pancreatic cancer. Aberrations of miRNA include overexpression of oncogenic miRs (Onco-miRs) or downregulation of so-called tumor suppressor TSG-miRs. Restitution of TSG-miRs in cancer cells through systemic delivery is a promising avenue for pancreatic cancer therapy. We have synthesized a lipid-based nanoparticle for systemic delivery of miRNA expression vectors to cancer cells (nanovector). The plasmid DNA-complexed nanovector is approximately 100 nm in diameter and shows no apparent histopathologic or biochemical evidence of toxicity upon intravenous injection. Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1). Systemic intravenous delivery with either miR-34a or miR-143/145 nanovectors inhibited the growth of MiaPaCa-2 subcutaneous xenografts (P < 0.01 for miR-34a; P < 0.05 for miR-143/145); the effects were even more pronounced in the orthotopic (intrapancreatic) setting (P < 0.0005 for either nanovector) when compared with vehicle or mock nanovector delivering an empty plasmid. Tumor growth inhibition was accompanied by increased apoptosis and decreased proliferation. The miRNA restitution was confirmed in treated xenografts by significant upregulation of the corresponding miRNA and significant decreases in specific miRNA targets (SIRT1, CD44 and aldehyde dehydrogenase for miR34a, and KRAS2 and RREB1 for miR-143/145). The nanovector is a platform with potential broad applicability in systemic miRNA delivery to cancer cells.",
author = "Dipankar Pramanik and Campbell, {Nathaniel R.} and Collins Karikari and Raghu Chivukula and Kent, {Oliver A.} and Mendell, {Joshua T.} and Anirban Maitra",
year = "2011",
month = "8",
doi = "10.1158/1535-7163.MCT-11-0152",
language = "English (US)",
volume = "10",
pages = "1470--1480",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice

AU - Pramanik, Dipankar

AU - Campbell, Nathaniel R.

AU - Karikari, Collins

AU - Chivukula, Raghu

AU - Kent, Oliver A.

AU - Mendell, Joshua T.

AU - Maitra, Anirban

PY - 2011/8

Y1 - 2011/8

N2 - Mis-expression of microRNAs (miRNA) is widespread in human cancers, including in pancreatic cancer. Aberrations of miRNA include overexpression of oncogenic miRs (Onco-miRs) or downregulation of so-called tumor suppressor TSG-miRs. Restitution of TSG-miRs in cancer cells through systemic delivery is a promising avenue for pancreatic cancer therapy. We have synthesized a lipid-based nanoparticle for systemic delivery of miRNA expression vectors to cancer cells (nanovector). The plasmid DNA-complexed nanovector is approximately 100 nm in diameter and shows no apparent histopathologic or biochemical evidence of toxicity upon intravenous injection. Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1). Systemic intravenous delivery with either miR-34a or miR-143/145 nanovectors inhibited the growth of MiaPaCa-2 subcutaneous xenografts (P < 0.01 for miR-34a; P < 0.05 for miR-143/145); the effects were even more pronounced in the orthotopic (intrapancreatic) setting (P < 0.0005 for either nanovector) when compared with vehicle or mock nanovector delivering an empty plasmid. Tumor growth inhibition was accompanied by increased apoptosis and decreased proliferation. The miRNA restitution was confirmed in treated xenografts by significant upregulation of the corresponding miRNA and significant decreases in specific miRNA targets (SIRT1, CD44 and aldehyde dehydrogenase for miR34a, and KRAS2 and RREB1 for miR-143/145). The nanovector is a platform with potential broad applicability in systemic miRNA delivery to cancer cells.

AB - Mis-expression of microRNAs (miRNA) is widespread in human cancers, including in pancreatic cancer. Aberrations of miRNA include overexpression of oncogenic miRs (Onco-miRs) or downregulation of so-called tumor suppressor TSG-miRs. Restitution of TSG-miRs in cancer cells through systemic delivery is a promising avenue for pancreatic cancer therapy. We have synthesized a lipid-based nanoparticle for systemic delivery of miRNA expression vectors to cancer cells (nanovector). The plasmid DNA-complexed nanovector is approximately 100 nm in diameter and shows no apparent histopathologic or biochemical evidence of toxicity upon intravenous injection. Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1). Systemic intravenous delivery with either miR-34a or miR-143/145 nanovectors inhibited the growth of MiaPaCa-2 subcutaneous xenografts (P < 0.01 for miR-34a; P < 0.05 for miR-143/145); the effects were even more pronounced in the orthotopic (intrapancreatic) setting (P < 0.0005 for either nanovector) when compared with vehicle or mock nanovector delivering an empty plasmid. Tumor growth inhibition was accompanied by increased apoptosis and decreased proliferation. The miRNA restitution was confirmed in treated xenografts by significant upregulation of the corresponding miRNA and significant decreases in specific miRNA targets (SIRT1, CD44 and aldehyde dehydrogenase for miR34a, and KRAS2 and RREB1 for miR-143/145). The nanovector is a platform with potential broad applicability in systemic miRNA delivery to cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=80051590849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051590849&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0152

DO - 10.1158/1535-7163.MCT-11-0152

M3 - Article

C2 - 21622730

AN - SCOPUS:80051590849

VL - 10

SP - 1470

EP - 1480

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 8

ER -